Out-of-pocket (OOP) spending for patients with heart failure with reduced ejection fraction rose in the event of a worsening heart failure event across the 4 phases of Medicare Part D coverage.
According to published research, in 2020, heart failure–related costs were a median $24,383 per year, with expenses related to hospitalizations accounting for just over 65%, or $15,879, of that total. As recently as that year, 5 million individuals were living with congestive heart failure and new diagnoses accounted for another 500,000 cases.
In addition, the cost totals represent an increase. In 2017, patient-related costs for a heart failure hospitalization averaged $14,631.
Now, a new analysis presented at this year’s American College of Cardiology 70th Scientific Session breaks down heart failure–related costs again—but this time, among those enrolled in Medicare Part D who specifically have heart failure with reduced ejection fraction (HFrEF). This is when left ventricular ejection fraction is 40% or less.
“Studies have shown high clinical and economic burden in patients with HFrEF who experience a worsening heart failure event (WHFE), but Medicare Part D out-of-pocket costs (OOP) are not well characterized,” the investigators noted. “This study evaluated OOP drug spending in chronic HFrEF patients with and without a worsening heart failure event.
Overall, within 1 year after their earliest HFrEF diagnosis, 26% of the entire patient cohort (n = 80,454) had a WHFE. And although the mean (SD) overall OOP costs were already elevated, at $1166 ($1205), those who had a WHFE had to fork over close to 17% more in OOP costs compared with those who did not have a WHFE: $1302 ($1273) vs $1117 ($1176), respectively.
Beyond OOP, or deductible, costs, the authors investigated the 3 other phases of Part D Medicare coverage: the initial coverage period, the coverage gap (or donut hole), and catastrophic coverage.
Not surprisingly, mean OOP costs rose with each successive phase and were higher among those with a WHFE vs those with no WHFE and overall, respectively:
The analysis also found fluctuating claims levels in each Medicare coverage phase. Just over one-third of the patients overall and in the WHFE and non-WHFE groups had a claim in the deductible phase (34.5%, 33.3%, and 34.9%, respectively). However, these numbers spiked in the initial coverage phase (93.3%, 95.2%, 92.6%) before dropping once again in the coverage gap (39.2%, 44.3%, 37.3%) and catastrophic (10.8%, 12.9%, 10.1%) phases.
For their analysis, the authors used 2018 Medicare 100% Part D fee-for-service claims data on patients with HFrEF and 12 months of enrollment in 2018 (N = 305,373). They defined the heart failure subtype as each participant having “1 inpatient or 2 outpatient claims of systolic heart failure or 1 systolic heart failure plus 1 heart failure outpatient claim.”
Different criteria were used to gauge a WHFE and comprised hospitalization for heart failure or need for an intravenous diuretic by the 12-month mark after receiving their HFrEF diagnosis.
“The findings suggest a high OOP cost burden in patients with chronic HFrEF,” the authors concluded, “especially in those following a WHFE.”
Reference
Fendrick M, Djatche L, Pulungan Z, et al. Part D out of pocket payments in Medicare beneficiaries with heart failure with reduced ejection fraction. Presented at: American College of Cardiology’s 70th Scientific Session; May 15-17, 2021. Virtual. Abstract 1038-07. https://www.abstractsonline.com/pp8/#!/9228/presentation/12576
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Health Equity and Access Weekly Roundup: March 23, 2024
March 23rd 2024The Center on Health Equity and Access covered disparities in hypertension, diabetic eye health, and hidradenitis suppurativa, along with the proposed legislation banning diversity, equity, and inclusion efforts in Alabama schools and the consequences in sickle cell care from the CDC guideline for opioid prescriptions.
Read More
CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.
Read More